Somatostatin analogs inhibit somatostatin release

E. Ipp, J. Rivier, R. E. Dobbs, M. Brown, W. Vale, Roger H Unger

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To determine if, like insulin, somatostatin inhibits its own secretion from the pancreas, nonimmunoreactive analogs of somatostatin were perfused in an isolated dog pancreaticoduodenal preparation using a nonrecirculating system. [D-Trp 8-D-Cys 14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine. When perfusion of the analog was discontinued, SLI release increased. At a concentration of 0.1 ng/ml, des Asn 5-[D-Trp 8]somatostatin lowered SLI levels significantly without significantly reducing glucagon levels. At a concentration of 1 ng/ml, des Asn 5-[D-Trp 8]somatostatin significantly inhibited SLI as well as insulin and glucagon release. Perfusion of glucagon at a concentration of 10 ng/ml failed to overcome the blockade of SLI and insulin release caused by 50 ng/ml des Asn 5-[D-Trp 8]somatostatin. The results are compatible with a direct inhibitory effect of somatostatin analogs upon SLI release and raise the possibility of a self-inhibiting action of the native hormone.

Original languageEnglish (US)
Pages (from-to)1270-1273
Number of pages4
JournalEndocrinology
Volume104
Issue number5
StatePublished - 1979

Fingerprint

Somatostatin
Glucagon
Insulin
Perfusion
Cholecystokinin
Arginine
somatostatin-like peptides
Pancreas
Hormones
Dogs
Trp(8)-somatostatin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Ipp, E., Rivier, J., Dobbs, R. E., Brown, M., Vale, W., & Unger, R. H. (1979). Somatostatin analogs inhibit somatostatin release. Endocrinology, 104(5), 1270-1273.

Somatostatin analogs inhibit somatostatin release. / Ipp, E.; Rivier, J.; Dobbs, R. E.; Brown, M.; Vale, W.; Unger, Roger H.

In: Endocrinology, Vol. 104, No. 5, 1979, p. 1270-1273.

Research output: Contribution to journalArticle

Ipp, E, Rivier, J, Dobbs, RE, Brown, M, Vale, W & Unger, RH 1979, 'Somatostatin analogs inhibit somatostatin release', Endocrinology, vol. 104, no. 5, pp. 1270-1273.
Ipp E, Rivier J, Dobbs RE, Brown M, Vale W, Unger RH. Somatostatin analogs inhibit somatostatin release. Endocrinology. 1979;104(5):1270-1273.
Ipp, E. ; Rivier, J. ; Dobbs, R. E. ; Brown, M. ; Vale, W. ; Unger, Roger H. / Somatostatin analogs inhibit somatostatin release. In: Endocrinology. 1979 ; Vol. 104, No. 5. pp. 1270-1273.
@article{8f8dc23dcd414863b7cd87e91a5dbcec,
title = "Somatostatin analogs inhibit somatostatin release",
abstract = "To determine if, like insulin, somatostatin inhibits its own secretion from the pancreas, nonimmunoreactive analogs of somatostatin were perfused in an isolated dog pancreaticoduodenal preparation using a nonrecirculating system. [D-Trp 8-D-Cys 14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine. When perfusion of the analog was discontinued, SLI release increased. At a concentration of 0.1 ng/ml, des Asn 5-[D-Trp 8]somatostatin lowered SLI levels significantly without significantly reducing glucagon levels. At a concentration of 1 ng/ml, des Asn 5-[D-Trp 8]somatostatin significantly inhibited SLI as well as insulin and glucagon release. Perfusion of glucagon at a concentration of 10 ng/ml failed to overcome the blockade of SLI and insulin release caused by 50 ng/ml des Asn 5-[D-Trp 8]somatostatin. The results are compatible with a direct inhibitory effect of somatostatin analogs upon SLI release and raise the possibility of a self-inhibiting action of the native hormone.",
author = "E. Ipp and J. Rivier and Dobbs, {R. E.} and M. Brown and W. Vale and Unger, {Roger H}",
year = "1979",
language = "English (US)",
volume = "104",
pages = "1270--1273",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Somatostatin analogs inhibit somatostatin release

AU - Ipp, E.

AU - Rivier, J.

AU - Dobbs, R. E.

AU - Brown, M.

AU - Vale, W.

AU - Unger, Roger H

PY - 1979

Y1 - 1979

N2 - To determine if, like insulin, somatostatin inhibits its own secretion from the pancreas, nonimmunoreactive analogs of somatostatin were perfused in an isolated dog pancreaticoduodenal preparation using a nonrecirculating system. [D-Trp 8-D-Cys 14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine. When perfusion of the analog was discontinued, SLI release increased. At a concentration of 0.1 ng/ml, des Asn 5-[D-Trp 8]somatostatin lowered SLI levels significantly without significantly reducing glucagon levels. At a concentration of 1 ng/ml, des Asn 5-[D-Trp 8]somatostatin significantly inhibited SLI as well as insulin and glucagon release. Perfusion of glucagon at a concentration of 10 ng/ml failed to overcome the blockade of SLI and insulin release caused by 50 ng/ml des Asn 5-[D-Trp 8]somatostatin. The results are compatible with a direct inhibitory effect of somatostatin analogs upon SLI release and raise the possibility of a self-inhibiting action of the native hormone.

AB - To determine if, like insulin, somatostatin inhibits its own secretion from the pancreas, nonimmunoreactive analogs of somatostatin were perfused in an isolated dog pancreaticoduodenal preparation using a nonrecirculating system. [D-Trp 8-D-Cys 14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine. When perfusion of the analog was discontinued, SLI release increased. At a concentration of 0.1 ng/ml, des Asn 5-[D-Trp 8]somatostatin lowered SLI levels significantly without significantly reducing glucagon levels. At a concentration of 1 ng/ml, des Asn 5-[D-Trp 8]somatostatin significantly inhibited SLI as well as insulin and glucagon release. Perfusion of glucagon at a concentration of 10 ng/ml failed to overcome the blockade of SLI and insulin release caused by 50 ng/ml des Asn 5-[D-Trp 8]somatostatin. The results are compatible with a direct inhibitory effect of somatostatin analogs upon SLI release and raise the possibility of a self-inhibiting action of the native hormone.

UR - http://www.scopus.com/inward/record.url?scp=0018769667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018769667&partnerID=8YFLogxK

M3 - Article

VL - 104

SP - 1270

EP - 1273

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 5

ER -